Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 8/20 | 0.45 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853715 | 0.92 | ALKBH1 (0.47) | ALKBH1PPARDFFAR1PPARAPPARG | |
| SCHEMBL2859204 | 0.91 | ALKBH1 (0.41) | ALKBH1PPARDPPARAPPARGCTSS | |
| SCHEMBL12876679 | 0.89 | MAPK14 (0.37) | PPARDPPARAPPARGCTSS | |
| SCHEMBL12876719 | 0.88 | ALKBH1 (0.44) | ALKBH1PPARDFFAR1PPARAPPARG | |
| SCHEMBL2859769 | 0.87 | ALKBH1 (0.47) | ALKBH1PPARAPPARG | |
| Trifluoroacetic Acid SCHEMBL2858914 | 0.87 | ALOX5AP (0.38) | PPARDPPARAPPARGCTSS | |
| SCHEMBL2857069 | 0.86 | PPARG (0.43) | ALKBH1PPARDPPARAPPARGCTSS | |
| SCHEMBL2856937 | 0.86 | SYK (0.39) | PPARDFFAR1PPARAPPARG | |
| SCHEMBL2859879 | 0.85 | PPARG (0.39) | RARARARBRARGPPARDPPARA | |
| SCHEMBL2859175 | 0.85 | PPARD (0.42) | PPARDFFAR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009123316-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | ALKBH1 1916/4885GCK 406/4885RARA 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.